Savant Capital LLC Has $2.36 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Savant Capital LLC grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 70,831 shares of the biotechnology company’s stock after acquiring an additional 849 shares during the quarter. Savant Capital LLC’s holdings in Exelixis were worth $2,359,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in EXEL. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 290 shares during the last quarter. Covestor Ltd grew its position in shares of Exelixis by 5.7% in the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 341 shares during the last quarter. Fifth Third Bancorp increased its position in Exelixis by 16.1% during the fourth quarter. Fifth Third Bancorp now owns 3,231 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 449 shares during the period. UMB Bank n.a. raised its holdings in Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 553 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its stake in Exelixis by 3.2% in the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 609 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

NASDAQ EXEL opened at $32.80 on Thursday. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $37.59. The company has a fifty day moving average price of $34.24 and a 200-day moving average price of $30.72. The firm has a market cap of $9.37 billion, a price-to-earnings ratio of 21.03, a PEG ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. On average, research analysts anticipate that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the transaction, the executive vice president now directly owns 278,665 shares of the company’s stock, valued at approximately $9,828,514.55. This trade represents a 3.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the sale, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 111,588 shares of company stock valued at $3,981,864. 2.85% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Stifel Nicolaus upped their target price on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 target price on shares of Exelixis in a research report on Wednesday, October 30th. Wells Fargo & Company increased their price target on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. JMP Securities reissued a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. Finally, Citigroup boosted their price target on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $37.00.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.